Introduction
============

Parkinsonian signs such as gait disturbances, rigidity, bradykinesia and tremor are common among older adults and significantly associated with negative outcomes such as dementia and death ([@b27-ndt-4-1267]; [@b16-ndt-4-1267]). A recent study shows that mild parkinsonian signs (MPS), especially rigidity, may frequently be observed among patients with amnestic mild cognitive impairment (MCI) and that these two conditions may share a common pathogenesis ([@b15-ndt-4-1267]). In an another study, subjects with MCI showed associated parkinsonian signs more frequently than controls without cognitive impairment. Among patients with MCI, lower levels of cognitive functioning, particularly in perceptual speed, were also associated with higher levels of parkinsonism ([@b4-ndt-4-1267]). In contrast to previous finding of a unique association between amnestic MCI and parkinsonism, the study by [@b4-ndt-4-1267] suggests that parkinsonian signs may be more prominent among individuals with nonamnestic forms of MCI (ie, with involvement of multiple areas). Moreover the association between MCI and parkinsonism is not completely explained by vascular risk factors or vascular disease.

A longitudinal cohort study involving older Catholic clergy membership concluded that persons with MCI also have impaired motor function, and the degree of impairment in lower extremity function is related to risk of Alzheimer's disease ([@b1-ndt-4-1267]).

The basis for these signs is unclear, but is likely to be multifactorial, including an age-associated decline in dopaminergic nigrostriatal activity, the early development of neurodegenetative (Lewy body or Alzheimer's diseases) pathologies in the basal ganglia, or the accumulations of vascular pathology in the brain ([@b14-ndt-4-1267]). Recent neuropathological studies indicate that neuronal loss in substantia nigra, partly related to tau lesions, is a major pathological substrate of extrapyramidal signs (EPS) in Alzheimer's disease (AD). EPS in elderly patients may be a surrogate marker for severe neuritic AD pathology ([@b3-ndt-4-1267]).

On the other hand, impairment of cognitive function has been demonstrated even in newly diagnosed Parkinson disease patients (PD), with deficits being most prominent in the domains of memory and executive functions; also, an older age at disease onset is likely to be an important determinant of cognitive dysfunction in PD ([@b21-ndt-4-1267]).

Based on these reports, we have tried to investigate how the association between MCI and MPS may be related to the evolution towards different type of dementias or other neurodegenerative disorders.

Methods
=======

In this retrospective investigation we considered a case-series of subjects fitting the criteria for MCI ([@b24-ndt-4-1267]), folllowed over a three-year period. During this time, a population of 135 consecutive cases was observed but, at the present moment, 16 subjects were lost at follow-up (7 died and 9 were not evaluated for poor compliance). The analysis was conducted on 119 cases (73.1 ± 5.7 years, M/F 50/69). The participants involved in this study were recruited from outpatients attending the Laboratory of Neuropsychology and the Alzheimer's Unit (UVA) at the Ospedale di Circolo and Fondazione Macchi in Varese, Italy.

After the first examination, MCI subjects were evaluated every 12 months to detect the patients who converted to dementia. We considered the baseline clinical picture in search of correlation between cognito-motor profile and the final diagnosis of dementia, as defined by the current clinical criteria ([@b18-ndt-4-1267]; [@b20-ndt-4-1267]; [@b26-ndt-4-1267]; [@b7-ndt-4-1267]; [@b17-ndt-4-1267]).

All cases underwent, at the baseline examination, a standard neurological examination, laboratory tests (routine blood samples, thyroid, B12 and folate, Venereal Disease Research Laboratory), neuroimaging investigation (brain computed tomography \[CT\]) in order to exclude secondary causes of brain organic dysfunction. The use of psychiatric drugs that may affect cognition or motor functions (such as antipsychotics or anticholinergic) was also excluded.

A validated CT-based weighted rating scale sensitive to detect different degrees of subcortical ischemic vascular disease (SIVD) was also calculated. This rating scale is valid and is sensitive to capture different degrees of SIVD associated with mild cognitive deterioration ([@b10-ndt-4-1267]).

Neurological examination included the motor portion of the Unified Parkinson Disease Rating Scale (UPDRS). MPS was determined by the presence of changes in axial function, rigidity or tremor ([@b16-ndt-4-1267]).

All the patients underwent a standardized neuropsychological battery, designed to assess cognitive functions that are generally involved in dementia: orientation, memory, attention, information processing speed, abstract reasoning, language and visuospatial ability. Tests administered included: Clinical Dementia Rating scale (CDR) ([@b20-ndt-4-1267]) for staging of dementia, Mini Mental State Examination (MMSE) ([@b8-ndt-4-1267]), Trail Making Test part A and B (TMT) ([@b11-ndt-4-1267]), and Mental Deterioration Battery (MDB) ([@b6-ndt-4-1267]). The MDB is comprised of eight tests, four are expressions from the processing of verbal material and four derive from the processing of visuospatial material. The verbal tests are: immediate (IR) and delayed recall (DR) of Rey's 15 words, word fluency (FAS), and phrase construction. The visuospatial tests are: Raven's 47 progressive colored matrices, immediate visual memory (IVM), and copying of drawings freehand (CD FH) and with landmarks (CD WL).

Affective symptoms were assessed using the Geriatric Depression Scale (GDS) (Yesavage et al 1983). GDS scores were used to exclude patients with severe depression and as control variable between the different groups. Instrumental activities of daily living (IADL) were also investigated ([@b13-ndt-4-1267]).

Statistical analysis
--------------------

Standardized and validated Italian language versions of all the tests are available. The cognitive performances of the patients were evaluated against normative data for the Italian population. Raw scores from each test were corrected for age, sex, and education and transformed into corrected scores, in accordance with Italian standardization studies.

A logistic regression analyses were performed using MPS status and type of dementia as the dependent variables and all the other relevant variables as predictors (SPSS version 13.0, SPSS Inc., Chicago, IL, USA).

Results
=======

Baseline evaluation
-------------------

Our population (119 cases of MCI) included, in according with the results of the baseline neuropsychological battery, 66 (55.5%) subjects with selective memory impairment (amnesic MCI) and 53 (45.5%) with an involvement of other cognitive areas (nonamnesic MCI). Among nonamnesic MCI the cognitive profile was characterized by a selective impairment of executive function or by a diffuse borderline performance.

According to Petersen criteria, MMSE scores, corrected by age and education, were within the normal range. At the time of the first examination study participants obtained a score equal to 0.5 (questionable dementia) at the CDR scale for staging of dementia, without significant impairment in social functioning (IADL).

MPS were detected in 22 subjects (18.5%) with postural instability and gait difficulty in 16 patients and dominant tremor in 6 cases. The presence of MPS were more frequent (p \< 0.05) among nonamnesic MCI (13/53) in respect to amnesic MCI (9/66). Demographic variables and cognitive performances among patients with (MPS+) and without MPS (MPS−) are reported in [Table 1](#t1-ndt-4-1267){ref-type="table"}. At the baseline observation the analyses of cognitive profile showed a worse performance of the TMT (B-A) in the MPS+ group (p \< 0.05), without significant differences for the other cognitive, affective and functional variables.

No significant difference was detected for GDS score between the two groups.

Furthermore in these cases the evaluation of basal brain CT scan pointed out the presence of a greater presence of moderate to severe subcortical vascular abnormalities -- SIVD ([Figure 1](#f1-ndt-4-1267){ref-type="fig"}) that, however, did not reached the statistical significance. The analysis of comorbility revealed an higher presence of vascular risk factors for nonamnesic group with a significant difference (p \< 0.05) for previous TIA or lacunar syndromes. These events had occurred before the onset of cognitive complaints thus excluding a direct cause--effect relationship.

Follow-up
---------

After a three-year follow-up 48/119 MCI patients (40.5%) had converted to possible or probable dementia of different types: Alzheimer's disease (AD), 31 (64.5%); Lewy Body dementia (LBD), 7 (14.5%); vascular dementia, 8 (16.5%); or fronto-temporal dementia (FTD), 2 (4.5%). Two cases of MPS group did not develop a progression towards dementia but were diagnosed as idiopathic PD. The classification of different type of dementia was made on the basis of the criteria exposed in the material and methods. Brain CT or magnetic resonance imaging (MRI) scans were repeated when necessary to confirm the clinical features of vascular dementia.

The annual rate of conversion to dementia of the entire population is reported in [Figure 2](#f2-ndt-4-1267){ref-type="fig"}: the group with MPS showed a more evident trend to the development of dementia.

MPS was present, at the baseline evaluation in 4/31 cases of AD, 2/7 of LBD, and 5/8 of vascular dementia. On this basis, the presence of MPS was significantly related to the development of vascular dementia (p \< 0.05). On the other hand patients with vascular dementia showed, at the baseline brain CT scan, moderate to severe SIVD, whereas SIVD alterations were similar among AD and LBD groups. Neuropsychological performance of the vascular dementia group was characterized by worse scores at TMT at the baseline examination, which did not reached a significant value probably due to the very low number of cases.

No significant difference in the occurrence of MPS was detectable at the first evaluation between patients converted to AD and LDB, the cognitive profile revealed only a worse performance in the copy of drawings among the LDB group.

Discussion
==========

Mild cognitive impairment represents a condition characterized by different neuropsychological profile (amnesic, nonamnesic, multiple areas defects). During the last years several clinical and noncognitive aspects were also investigated such as comorbidity, the prevalence of psychiatric syndromes and symptoms ([@b2-ndt-4-1267]) and, recently, the medical decision making-capacity of these subject ([@b22-ndt-4-1267]). The present study focused the attention on the presence of MPS in a group of amnesic and nonamnesic MCI followed for a three-year period. Our data confirm the relevance of the association between MPS and MCI and might indicate an higher chance for these cases to develop dementing conditions related to vascular disease.

In the study by [@b16-ndt-4-1267], MPS, especially rigidity, are associated with amnestic MCI. Moreover the authors suggested that MPS and MCI may share similar pathogenesis. The observation that MPS were associated with vascular risk factors and vascular disease suggests that cerebrovascular disease may contribute to both conditions.

In contrast to this finding of a unique association between amnestic MCI and MPS, the results of [@b4-ndt-4-1267] suggested that MPS may be more prominent among individuals with non-amnestic MCI as opposed to amnestic MCI. Another study demonstrated that the severity of MPS was related to the severity of cognitive impairment, in particular nonmemory functions, and also to a different pattern of psycho-behavioral symptoms ([@b25-ndt-4-1267]).

In our study, MPS occurred in 22 out of 119 cases (18.5%) that differed from the rest of population for a greater impairment of executive function and, subsequently, a greater number of cases with nonamnesic MCI. In particular a pathological or borderline score at the TMT significantly divided the two groups with and without MPS. This association, as observed by Boyle and colleagues, could indicate that the involvement of executive functions is consistent with the dysfunction of fronto-subcortical systems and the development of parkinsonian signs ([@b27-ndt-4-1267]).

Among MPS patients the analysis of movement disorders showed a prevalent presence of postural instability and gait disturbances (PIGD). With regard to this finding a recent study confirmed that PIGD motor subtype was associated with a faster rate of cognitive decline in PD and may be considered a risk factor for incident dementia in PD ([@b5-ndt-4-1267]).

Over a three-year period, 48 MCI cases converted to dementia and the presence of MPS signs, at the baseline evaluation, is significantly related to the development of SIVD. Among these two groups, the presence of vascular abnormalities was, as expected, showed more evidence for vascular dementia. No difference between AD and LBD was detected.

A recent study on a large group of MCI patients confirmed that, in the context of pervasive episodic memory impairment, tests assessing the free recall of verbal material following a delay interval demonstrated the greater sensitivity to memory deficits of amnesic MCI subjects who developed AD ([@b23-ndt-4-1267]). On the contrary, strategic cerebrovascular lesions detected by MRI in patients with CDR score equivalent to 0.5 were associated with impaired TMT B performances. In particular executive dysfunction was probably based on an impaired fronto-subcortical circuit ([@b12-ndt-4-1267]). In some vascular dementia subtypes, particularly those caused by subcortical microvascular disease, dementia may be preceded by MCI, which has similar domains of cognitive impairment and similar progressive course that may mimic AD (Meyer et al 1981).

Although a MRI examination was available only for few cases and a CT weighted scale was used, these findings also indicated that MCI with MPS is partly explained by the occurrence of vascular ischemic abnormalities.

Moreover during the follow-up period we observed several cases converted to different types of dementia including LBD, but 2 patients also developed a PD associated with MCI. Two different studies showed that, in newly diagnosed PD, a cognitive dysfunction ranging from 24% to 36% was detectable ([@b9-ndt-4-1267]; [@b15-ndt-4-1267]). This finding could indicate that cognitive dysfunctions in early PD may reflects neuropathological changes that are distinct from those associated with motor disorders.

The overlap between these different conditions suggests that the mechanisms underlying MPS are probably heterogeneous with a range of potential pathophysiological processes that include nerodegenerative and vascular pathologies ([@b14-ndt-4-1267]).
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###### 

Demographic and clinical variables of patients with (MPS+) and without MPS (MPS−)

  Demographic variables                                        MPS+ (N, 22)                                        MPS− (N, 97)
  ------------------------------------------------------------ --------------------------------------------------- --------------
  Age                                                          74 ± 6.1                                            72.8 ± 5.3
  Sex m/f                                                      12/10                                               41/56
  Education                                                    6.9 ± 3.1                                           7.1 ± 3.4
  Dementia variables                                                                                               
  GDS                                                          10.2 ± 5.1                                          8.7 ± 4.4
  IADL                                                         7.4 ± 0.6                                           7.6 ± 0.4
  MMSE                                                         26.9 ± 1.6                                          27.2 ± 1.8
  Comorbility                                                                                                      
  Hypertension                                                 11 (50)                                             31 (32)
  Diabetes                                                     2 (9)                                               5 (5)
  TIA/minor stroke[°](#tfn2-ndt-4-1267){ref-type="table-fn"}   4[\*](#tfn1-ndt-4-1267){ref-type="table-fn"} (18)   3 (3)
  Ischemic cardiopathy                                         4 (18)                                              14 (14.5)

**Notes:** p \< 0.05 Chi-square test;

Events occurred before the onset of cognitive complaints thus excluding a direct cause-effect relationship.

**Abbreviations:** GDS, geriatric depression scale; IADL, instrumental activity of daily living; MMSE, mini mental state examination.
